RxDoctor Payments Data

David Engel, MD

Cardiovascular Disease · New York, NYNPI 1043397144

Payments from drug & device makers

$171,634in general payments, 2019–2025

Across 222 payments — averaging $773.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$87K
  • Abbott$82K
  • Novartis$615
  • Johnson & Johnson$324
  • Pfizer$233
  • Amgen$228
  • plus $760 from 11 others

What the payments were for

  • Consulting fees$82,25097%
  • Food & beverage$2,1052%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,634 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$363,807
Medicare patients
1,406
Services billed
3,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban470$552,412
XareltoRivaroxaban232$269,525
EntrestoSacubitril/Valsartan74$95,845
Repatha SureclickEvolocumab72$63,279
MounjaroTirzepatide22$27,456
OzempicSemaglutide14$25,705
JardianceEmpagliflozin13$17,993
DiovanValsartan22$16,527
Metoprolol Succinate960$16,080
Atorvastatin Calcium748$8,837
PradaxaDabigatran Etexilate Mesylate18$6,177
Amlodipine Besylate652$6,084
Rosuvastatin Calcium373$5,979
Praluent PenAlirocumab11$5,143
Losartan Potassium349$4,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$552,412470 claims
Johnson & JohnsonXarelto$324$269,525232 claims
NovartisEntresto, Diovan$615$112,37296 claims
Novo NordiskOzempic$92$25,70514 claims
Boehringer IngelheimJardiance, Pradaxa$116$24,17031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →